Logo image of CTCX

CARMELL CORP (CTCX) Stock Fundamental Analysis

NASDAQ:CTCX - Nasdaq - US1429221039 - Common Stock - Currency: USD

0.1973  +0 (+1.39%)

Fundamental Rating

0

Taking everything into account, CTCX scores 0 out of 10 in our fundamental rating. CTCX was compared to 563 industry peers in the Biotechnology industry. CTCX has a bad profitability rating. Also its financial health evaluation is rather negative. CTCX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CTCX had negative earnings in the past year.
CTCX had a negative operating cash flow in the past year.
CTCX Yearly Net Income VS EBIT VS OCF VS FCFCTCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -1047.34%, CTCX is doing worse than 97.90% of the companies in the same industry.
Industry RankSector Rank
ROA -1047.34%
ROE N/A
ROIC N/A
ROA(3y)-8.43%
ROA(5y)N/A
ROE(3y)-21.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTCX Yearly ROA, ROE, ROICCTCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTCX Yearly Profit, Operating, Gross MarginsCTCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, CTCX has more shares outstanding
Compared to 1 year ago, CTCX has a worse debt to assets ratio.
CTCX Yearly Shares OutstandingCTCX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
CTCX Yearly Total Debt VS Total AssetsCTCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

CTCX has an Altman-Z score of -52.95. This is a bad value and indicates that CTCX is not financially healthy and even has some risk of bankruptcy.
CTCX's Altman-Z score of -52.95 is on the low side compared to the rest of the industry. CTCX is outperformed by 93.88% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -52.95
ROIC/WACCN/A
WACCN/A
CTCX Yearly LT Debt VS Equity VS FCFCTCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.31 indicates that CTCX may have some problems paying its short term obligations.
CTCX's Current ratio of 0.31 is on the low side compared to the rest of the industry. CTCX is outperformed by 94.41% of its industry peers.
CTCX has a Quick Ratio of 0.31. This is a bad value and indicates that CTCX is not financially healthy enough and could expect problems in meeting its short term obligations.
CTCX's Quick ratio of 0.29 is on the low side compared to the rest of the industry. CTCX is outperformed by 94.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.29
CTCX Yearly Current Assets VS Current LiabilitesCTCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CTCX have decreased strongly by -335.78% in the last year.
Looking at the last year, CTCX shows a very negative growth in Revenue. The Revenue has decreased by -99.12% in the last year.
EPS 1Y (TTM)-335.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
Revenue 1Y (TTM)-99.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.45%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CTCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTCX Price Earnings VS Forward Price EarningsCTCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTCX Per share dataCTCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CTCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARMELL CORP

NASDAQ:CTCX (3/7/2025, 8:16:34 PM)

0.1973

+0 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners8.88%
Inst Owner Change-10.09%
Ins Owners11.63%
Ins Owner Change0%
Market Cap5.94M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 181.18
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS-0.13
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1047.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.43%
ROA(5y)N/A
ROE(3y)-21.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.29
Altman-Z -52.95
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-335.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1727.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1727.38%
OCF growth 3YN/A
OCF growth 5YN/A